FOOD AND DRUG ADMINISTRATION

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

CELLULAR, TISSUE AND GENE THERAPIES ADVISORY COMMITTEE

Meeting #44, Teleconference

July 26, 2007

National Institutes of Health, Building 29B, Conference Rooms A/B

Bethesda, Maryland

 

 

AGENDA

                        OPEN SESSION

11:00 a.m.  Eastern Time        

                                    Opening Remarks

                                                Walter Urba, M.D., Ph.D., Chair

                                   

                                    Roll-Call and Conflict of Interest Statement

                                                Gail Dapolito, Executive Secretary

 

11:10                           Introduction – Site Visit Process

                                                Kathryn Carbone, M.D., Associate Director for Research

                                                Center for Biologics Evaluation and Research

 

11:30                           Overview Research – Office of Cellular, Tissue and Gene Therapies                                                 (OCTGT)

                                                Celia Witten, M.D., Ph.D., Director, OCTGT

 

11:40                           Overview Research – Gene Transfer and Immunogenicity Branch (GTIB)

                                                Eda Bloom, Ph.D., Chief, GTIB

 

12:10 p.m.                   Q&A

                                   

 

12:15                           Overview Research - Office of Biotechnology Products (OBP)

                                                Elizabeth Shores, Ph.D., Deputy Director, (OBP)

 

12:20                           Overview Research – Division of Monoclonal Antibodies (DMA), OBP

                                                Kathleen Clouse, Ph.D., Director, DMA

 

12:35                           Q&A

 

12:40                           Overview Research – Division of Therapeutic Proteins (DTP), OBP

                                                Amy Rosenberg, M.D., Director, DTP

 

1:10                             Q&A

 

1:15                             Open Public Hearing

                                               

2:15                 CLOSED SESSION

 

3:30 p.m.         Adjourn